论文部分内容阅读
作者为研究抗纤溶药物凝血酸(tranexamic acid,TA)在急性髓性白血病(AML)诱导化疗中对血小板减少的临床效果和安全性,于54例连续的AML诱导和强化巩固化疗期,当患者血小板数<50×10g/L时口服TA 1克每6小时一次,直至血小板数上升超过20×10~9/L。不论血小板数多少。当口腔、粘膜或明显皮肤出血征象时输注血小板。每次输注6—8袋随机献血者的血小板(平均每次输注7.5袋),仅少数患者接受单一供体血小板浓缩物。54例AML患者共接受78次诱导疗程,37例(68.5％)获得完全缓解,其后35例接受53次强化巩固疗程。结果在诱导期和巩固治疗期患者血小板数<20×10~9/L的平均天数分别为14.4±7.4天和8.4±8.5天,母个疗程分别输注血小板4.6±4.1次和
In order to study the clinical effect and safety of anti-fibrinolytic tranexamic acid (TA) on thrombocytopenia induced by chemotherapy-induced acute myeloid leukemia (AML), 54 consecutive AML-induced and intensive consolidation chemotherapy periods Patients with platelet count <50 × 10g / L TA 1 g once every 6 hours until the number of platelets increased more than 20 × 10 ~ 9 / L. No matter how many platelets. When the mouth, mucous membranes or obvious signs of bleeding skin transfusion of platelets. For each 6-8 random blood donors’ platelets (an average of 7.5 bags per infusion), only a minority of patients receive a single donor platelet concentrate. A total of 54 patients with AML received 78 induction courses, 37 (68.5%) achieved complete remission, and 35 received 53 intensive consolidation regimens. Results The average days of platelet count <20 × 10 ~ 9 / L during induction and consolidation therapy were 14.4 ± 7.4 days and 8.4 ± 8.5 days, respectively. Platelets were infused 4.6 ± 4.1 times